Market Overview:
The global piperacillin and tazobactam injection market is expected to register a CAGR of 5.8% during the forecast period, 2018-2030. The hospital segment is expected to dominate the market in terms of revenue share during the forecast period. North America dominates the global piperacillin and tazobactam injection market, followed by Europe and Asia Pacific.
Product Definition:
Piperacillin and tazobactam injection is a combination antibiotic used to treat a wide variety of bacterial infections. It works by killing the bacteria or preventing them from growing.
Piperacillin Injection:
Piperacillin and tazobactam are the two most important antibiotics used in the treatment of bacterial infections. They are narrow spectrum antibiotics, which means that they only fight bacteria, while leaving good bacteria unaffected. These drugs belong to a group of medications called Aminoglycosides. The drug was discovered in 1948 and was first marketed under the brand name “Allerga” byethanine GmbH & Co., KG now Novartis AG.
Tazobactam Injection:
Tazobactam is a synthetically produced antibiotic drug. It was developed by Eisai Co., Ltd. in Japan and patented in 1980. Tazobactam has been approved for the treatment of urinary tract infections (UTIs) and pneumonia caused by beta-lactams resistant to every other antibiotics, including aminoglycosides, cephalosporins, macrolides, tetracyclines and others.
Application Insights:
The hospital application segment led the market and accounted for more than 70.0% share of the global revenue in 2017. The growing number of hospitals, particularly in developing countries such as India, China and Brazil is expected to be a major factor driving product demand over the forecast period. In addition, increasing investments by governments in healthcare infrastructure development are likely to further propel piperacillin injection demand within hospitals globally.
Piperacillin-tazobactam is used for treatment of severe pneumonia caused by susceptible bacteria including Staphylococcus aureus and Streptococcus pneumoniae among others that cause infections during respiratory tract procedures such as nasal swabs or surgeries resulting in lung damage or infection at a deeper level causing severe breathing problems.
Regional Analysis:
North America dominated the global piperacillin and tazobactam injection market in 2017. This is attributed to the presence of a large number of players, high adoption rate for new technologies, well-established healthcare infrastructure and favorable reimbursement policies. The region is expected to maintain its dominance during the forecast period as well owing to increasing awareness about these products and their benefits coupled with rising prevalence of resistant bacteria.
Asia Pacific market for piperacillin and tazobactam injection is anticipated to witness lucrative growth over the forecast period owing to improving economic conditions in emerging countries such as India & China & South Korea; growing medical tourism; increasing investments by international companies in this region; etc’ These factors are expected contribute towards rapid expansion of hospital chains, clinics, diagnostic laboratories across Asia Pacific thus fueling product demand over the projected time frame.
Growth Factors:
- Increasing incidence of infectious diseases: The increasing incidence of infectious diseases is one of the key growth drivers for the Piperacillin and tazobactam Injection market. This is because infections caused by bacteria are on the rise, and there is a need for effective antibiotics to treat these infections. Piperacillin and tazobactam are two such antibiotics that have been proven to be highly effective in treating a variety of bacterial infections.
- Rising demand for piperacillin and tazobactam in hospitals: The rising demand for piperacillin and tazobactam in hospitals is another key growth driver for this market. This is because these drugs are increasingly being used as first-line treatments against various types of bacterial infections, including those that are resistant to other antibiotics. As a result, hospital pharmacies are stocking up on these drugs to meet the growing demand from patients requiring them for treatment purposes.
Scope Of The Report
Report Attributes
Report Details
Report Title
Piperacillin and tazobactam Injection Market Research Report
By Type
Piperacillin Injection, Tazobactam Injection
By Application
Hospital, Clinic
By Companies
Qilu Pharmaceutical, Pfizer Healthcare, Fresenius Kabi AG, Aurobindo Pharma, Sandoz Inc, NCPC, REYOUNG, Yuhan Corporation, LKPC, Nectar Lifesciences, Sterile India
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
242
Number of Tables & Figures
170
Customization Available
Yes, the report can be customized as per your need.
Global Piperacillin and tazobactam Injection Market Report Segments:
The global Piperacillin and tazobactam Injection market is segmented on the basis of:
Types
Piperacillin Injection, Tazobactam Injection
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Qilu Pharmaceutical
- Pfizer Healthcare
- Fresenius Kabi AG
- Aurobindo Pharma
- Sandoz Inc
- NCPC
- REYOUNG
- Yuhan Corporation
- LKPC
- Nectar Lifesciences
- Sterile India
Highlights of The Piperacillin and tazobactam Injection Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Piperacillin Injection
- Tazobactam Injection
- By Application:
- Hospital
- Clinic
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Piperacillin and tazobactam Injection Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Piperacillin and tazobactam Injection is a combination antibiotic medication used to treat infections caused by bacteria. It is usually given as an injection into a muscle or under the skin. Piperacillin and tazobactam Injection can also be taken by mouth.
Some of the major companies in the piperacillin and tazobactam injection market are Qilu Pharmaceutical, Pfizer Healthcare, Fresenius Kabi AG, Aurobindo Pharma, Sandoz Inc, NCPC, REYOUNG, Yuhan Corporation, LKPC, Nectar Lifesciences, Sterile India.
The piperacillin and tazobactam injection market is expected to grow at a compound annual growth rate of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Piperacillin and tazobactam Injection Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Piperacillin and tazobactam Injection Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Piperacillin and tazobactam Injection Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Piperacillin and tazobactam Injection Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Piperacillin and tazobactam Injection Market Size & Forecast, 2018-2028
4.5.1 Piperacillin and tazobactam Injection Market Size and Y-o-Y Growth
4.5.2 Piperacillin and tazobactam Injection Market Absolute $ Opportunity
Chapter 5 Global Piperacillin and tazobactam Injection Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Piperacillin and tazobactam Injection Market Size Forecast by Type
5.2.1 Piperacillin Injection
5.2.2 Tazobactam Injection
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Piperacillin and tazobactam Injection Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Piperacillin and tazobactam Injection Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Piperacillin and tazobactam Injection Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Piperacillin and tazobactam Injection Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Piperacillin and tazobactam Injection Analysis and Forecast
9.1 Introduction
9.2 North America Piperacillin and tazobactam Injection Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Piperacillin and tazobactam Injection Market Size Forecast by Type
9.6.1 Piperacillin Injection
9.6.2 Tazobactam Injection
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Piperacillin and tazobactam Injection Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Piperacillin and tazobactam Injection Analysis and Forecast
10.1 Introduction
10.2 Europe Piperacillin and tazobactam Injection Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Piperacillin and tazobactam Injection Market Size Forecast by Type
10.6.1 Piperacillin Injection
10.6.2 Tazobactam Injection
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Piperacillin and tazobactam Injection Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Piperacillin and tazobactam Injection Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Piperacillin and tazobactam Injection Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Piperacillin and tazobactam Injection Market Size Forecast by Type
11.6.1 Piperacillin Injection
11.6.2 Tazobactam Injection
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Piperacillin and tazobactam Injection Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Piperacillin and tazobactam Injection Analysis and Forecast
12.1 Introduction
12.2 Latin America Piperacillin and tazobactam Injection Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Piperacillin and tazobactam Injection Market Size Forecast by Type
12.6.1 Piperacillin Injection
12.6.2 Tazobactam Injection
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Piperacillin and tazobactam Injection Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Piperacillin and tazobactam Injection Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Piperacillin and tazobactam Injection Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Piperacillin and tazobactam Injection Market Size Forecast by Type
13.6.1 Piperacillin Injection
13.6.2 Tazobactam Injection
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Piperacillin and tazobactam Injection Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Piperacillin and tazobactam Injection Market: Competitive Dashboard
14.2 Global Piperacillin and tazobactam Injection Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Qilu Pharmaceutical
14.3.2 Pfizer Healthcare
14.3.3 Fresenius Kabi AG
14.3.4 Aurobindo Pharma
14.3.5 Sandoz Inc
14.3.6 NCPC
14.3.7 REYOUNG
14.3.8 Yuhan Corporation
14.3.9 LKPC
14.3.10 Nectar Lifesciences
14.3.11 Sterile India
